The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson’s disease  with motor fluctuations. We have led the clinical trial in Spain with this drug. Our patients are continuing to use it during the open label extension.

Compartir:

Grifols has reported to the press the positive result of the AMBAR trial in patients with Alzheimer’s disease in a moderate phase. Our unit (located in the General University Hospital of Catalonia) participated in this phase II clinical trial. Patients were treated with several plasmapheresis and albumin replacement, with or without immunoglobulins administration, compared to…

Compartir:

The Pasqual Maragall Foundation develops a method based on magnetic resonance imaging It allows to reduce to 67% the selective tests. BARCELONA Given the difficulties of finding an effective treatment to cure Alzheimer’s disease, efforts to prevent the disease multiply. One of the entities that works in this line is the Pasqual Maragall Foundation, which…

Compartir:

We have been selected to evaluate an innovative therapy in this terrible disease. We will begin a Ib Phase clinical trial to evaluate the safety of an antiTau monoclonal antibody. If it is positive, we will participate in the development of the phase II trial to also check the efficacy and safety of different doses…

Compartir:

The UDIC will shortly begin a clinical trial to evaluate the subcutaneous administration of levodopa, through continuous perfusion, to treat motor fluctuations in advanced Parkinson’s. For the first time, this use of an “ultra concentrated” levodopa that can allow its subcutaneous administration. The use of a continuous infusion pump can obtsin an adequate control of…

Compartir:

Our Unit participated in a Phase II clinical trial, with a monoclonal anti-amyloid in Alzheimer’s, which was positive. We have been selected to develop the phase III trial with this Eisai drug.  

Compartir:

Our Unit has surpassed two centers from the United States in the randomization of patients included in a clinical trial with a neuromodulator. In addition, the sum of our activity in Sant Cugat and in Manresa has reached more than 73% of the all patients included in Spain.

Compartir:

On February 7, 2019, at the Exchange Conference UIC (Universitat Internacional de Catalunya) and the ACE Foundation, which took place in the Campus Salut of the UIC, our Clinical Research Unit (UDIC) presented its project to carry out clinical trials in a network system, involving different health centers for the performance of neurological clinical trials. In particular, this project…

Compartir:

Our unit has received the congratulations of a patient, after finishing his participation in a clinical trial in Parkinson’s disease. It reflects a human experience of the collaboration of different professionals, focused on patient’s care.  

Compartir:

Our clinical trials unit will start a new phase I trial in patients with early Parkinson’s disease. Patients will be included in different cohorts, single dose and ascending doses, in patients with or without mutations in the LRRK2 gene, by means of an intrathecal administration of an antisense oligonucleotide. Only 62 patients will participate in 17…

Compartir:
Page 1 of 21 2

No dude en llamarnos        1-+34 935 656 000